Compare EIC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | NKTR |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 2.2B |
| IPO Year | 2018 | 1996 |
| Metric | EIC | NKTR |
|---|---|---|
| Price | $9.63 | $70.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $12.63 | ★ $146.67 |
| AVG Volume (30 Days) | 81.4K | ★ 487.3K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $9.17 | $33.40 |
| 52 Week High | $13.55 | $109.00 |
| Indicator | EIC | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 36.65 |
| Support Level | $9.33 | $67.11 |
| Resistance Level | $10.14 | $76.63 |
| Average True Range (ATR) | 0.11 | 2.73 |
| MACD | -0.03 | -0.90 |
| Stochastic Oscillator | 32.08 | 11.79 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.